BRIDGEWATER, N.J., October 8 - Sanofi-aventis U.S. announced today that it will streamline U.S. Pharmaceutical Operations as part of the company’s ongoing transformation to better respond to patients and customers in a challenging healthcare marketplace. The restructuring will include an estimated 25% work force reduction in U.S. Pharmaceutical Operations, eliminating approximately 1,700 positions in total. These decisions will be finalized by mid-December.
Of the 13,000 people employed by sanofi-aventis in the United States, currently 6,900 are employed in the Pharmaceutical Operations division. Other affiliates of sanofi-aventis in the United States include Research & Development, sanofi pasteur vaccines, BiPar and Chattem, the company’s consumer healthcare business.
No comments:
Post a Comment